Evidence map›Paper›PMID 33506575›Full record

ArticleCancer science2021

Conditional Ror1 knockout reveals crucial involvement in lung adenocarcinoma development and identifies novel HIF-1α regulator.

Hisanori Isomura, Ayumu Taguchi, Taisuke Kajino, Naoya Asai, Masahiro Nakatochi, Seiichi Kato, Keiko Suzuki, Kiyoshi Yanagisawa, Motoshi Suzuki, Teruaki Fujishita and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Role of the Ror family receptors in Wnt5a signaling.In vitro cellular & developmental biology. Animal · 2024
    Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Hisanori IsomuraDivision of Molecular Carcinogenesis, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Ayumu TaguchiDivision of Molecular Diagnostics, Aichi Cancer Center Research Institute, Nagoya, Japan.
Taisuke KajinoDivision of Molecular Carcinogenesis, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Naoya AsaiDepartment of Pathology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Masahiro NakatochiPublic Health Informatics Unit, Department of Integrated Health Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID https://orcid.org/0000-0002-1838-4837
Seiichi KatoDepartment of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan.
Keiko SuzukiDivision of Molecular Carcinogenesis, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kiyoshi YanagisawaDivision of Molecular Carcinogenesis, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Motoshi SuzukiDivision of Molecular Carcinogenesis, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID https://orcid.org/0000-0003-0682-5006
Teruaki FujishitaDivision of Pathophysiology, Aichi Cancer Center Research Institute, Nagoya, Japan.
Tomoya YamaguchiDivision of Molecular Carcinogenesis, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID https://orcid.org/0000-0001-6933-543X
Masahide TakahashiDepartment of Pathology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Takashi TakahashiDivision of Molecular Carcinogenesis, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID https://orcid.org/0000-0003-0615-7001
Aichi Cancer Center · JPNagoya University · JPFujita Health University · JP

Funding

Japan Agency for Medical Research and Development JP18cm0106107Japan Agency for Medical Research and Development JP20cm0106107the Japan Society for the Promotion of Science 16H02468
6 · The paper itself

Abstract

We previously reported that ROR1 is a crucial downstream gene for the TTF-1/NKX2-1 lineage-survival oncogene in lung adenocarcinoma, while others have found altered expression of ROR1 in multiple cancer types. Accumulated evidence therefore indicates ROR1 as an attractive molecular target, though it has yet to be determined whether targeting Ror1 can inhibit tumor development and growth in vivo. To this end, genetically engineered mice carrying homozygously floxed Ror1 alleles and an SP-C promoter-driven human mutant EGFR transgene were generated. Ror1 ablation resulted in marked retardation of tumor development and progression in association with reduced malignant characteristics and significantly better survival. Interestingly, gene set enrichment analysis identified a hypoxia-induced gene set (HALLMARK_HYPOXIA) as most significantly downregulated by Ror1 ablation in vivo, which led to findings showing that ROR1 knockdown diminished HIF-1α expression under normoxia and clearly hampered HIF-1α induction in response to hypoxia in human lung adenocarcinoma cell lines. The present results directly demonstrate the importance of Ror1 for in vivo development and progression of lung adenocarcinoma, and also identify Ror1 as a novel regulator of Hif-1α. Thus, a future study aimed at the development of a novel therapeutic targeting ROR1 for treatment of solid tumors such as seen in lung cancer, which are frequently accompanied with a hypoxic tumor microenvironment, is warranted.

Indexed as

Adenocarcinoma of LungAnimalsCell Line, TumorDown-RegulationGene Expression Regulation, NeoplasticHumansHypoxiaHypoxia-Inducible Factor 1, alpha SubunitLung NeoplasmsMiceMice, Inbred BALB CMice, Inbred C57BLMice, KnockoutMice, TransgenicOncogenesReceptor Tyrosine Kinase-like Orphan ReceptorsHif1a protein, mouseHypoxia-Inducible Factor 1, alpha SubunitReceptor Tyrosine Kinase-like Orphan ReceptorsRor1 protein, mouseThyroid Nuclear Factor 1EGFRgenetically engineered mouse modelHIF-1αlung adenocarcinomaROR1

Identifiers

PMID33506575
PMCPMC8019194
OpenAlexW3124312803

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.